FC1 Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner

Hausenloy, Derek J; Wynne, Abigail; Theodorou, Louise; Mocanu, Mihaela M.; Yellon, Derek M.

doi:10.1136/hrt.2010.205781.7

Heart

2010

DOI: 10.1136/hrt.2010.205781.7

|View full text |Cite

FC1 Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner

Derek J Hausenloy

Abigail Wynne

Louise Theodorou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2013

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Direct cardiovascular effects of glucagon like peptide-1

Sheikh

2013

Diabetol Metab Syndr

View full text Add to dashboard Cite

Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly reduce macrovascular morbidity and mortality. Among emerging anti-diabetic candidates, glucagon like peptide-1 (GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects. The direct cardiovascular effects of GLP-1 and its analogs remain the focus of this review.

show abstract

Direct cardiovascular effects of glucagon like peptide-1

Sheikh

2013

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

Potential cardiovascular effects of incretin-based therapies

Deacon¹,

Marx

2012

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Glucagon-like peptide (GLP)-1 agonists and dipeptidyl peptidase-4 inhibitors are two classes of drugs that have been approved for treatment of Type 2 diabetes mellitus, based upon the glucose-lowering actions of the gastrointestinal hormone GLP-1. However, GLP-1 receptors are also present in cardiovascular tissues. Data from animal and in vitro studies suggest that GLP-1 may have cardioprotective effects and improve myocardial and endothelial dysfunction. Clinical data demonstrating cardiovascular effects are more limited, and there is some evidence that incretin-based therapies may be associated with improvements in cardiovascular risk factors. Large prospective cardiovascular outcome trials are underway to examine the cardiovascular safety of incretin-based therapies, and may reveal whether these agents are associated with any reduction in cardiovascular adverse events in patients with Type 2 diabetes mellitus.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

FC1 Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner

Cited by 2 publications

References 0 publications

Direct cardiovascular effects of glucagon like peptide-1

Direct cardiovascular effects of glucagon like peptide-1

Potential cardiovascular effects of incretin-based therapies

Contact Info

Product

Resources

About